QUIMOX
Manufacturer
ALFA INTES INDUSTRIA TERAPEUTICA SPLENDORE S.R.L., Italy
Applicant company
TV
Active ingredient
Moxifloxacin
Content
1,25mg
Shelf life
24 months
Dosage Form
Ophthalmic solution
Package
Box of 3 Aluminium strips of 10 containers x 0.25 ml
Visa Number
800115772624
Issuing Date
12/8/2024
Therapeutic area
Ophthalmologicals; anti-infectives, other anti-infectives
Indication
Quimox is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following microorganisms:
Aerobic Gram-positive microorganisms:
Corynebacterium species
Microbacterium species
Micrococcus luteus (including strains resistant to erythromycin, gentamycin, tetracycline and/or trimethoprim).
Staphylococcus aureus (including strains resistant to methicillin, erythromycin, gentamycin, ofloxacin, tetracycline and/or trimethoprim).
Staphylococcus epidermidis (including strains resistant to methicillin, erythromycin, gentamycin, ofloxacin, tetracycline and/or trimethoprim).
Staphylococcus haemolyticus (including strains resistant to methicillin, erythromycin, gentamycin, ofloxacin, tetracycline and/or trimethoprim).
Staphylococcus hominis (including strains resistant to methicillin, erythromycin, gentamycin, ofloxacin, tetracycline, and/or trimethoprim).
Staphylococcus warneri (including strains resistant to erythromycin).
Streptococcus pneumoniae (including strains resistant to penicillin, erythromycin, tetracycline, and/or trimethoprim).
Stretococcus viridans (including strains resistant to penicillin, erythromycin, tetracycline, and/or trimethoprim).
Aerobic Gram-negative microorganisms:
Acinetobacter species
Haemophilus alconae (including ampicillin-resistant strains).
Haemophilus influenzae (including ampicillin-resistant strains).
Haemophilus parainfluenzae
Klensialla pneumoniae
Moraxella cattarrhalis
Pseudomonas aeruginosa.
Other microorganisms:
Chlammydia trachomatis
Effectiveness on this microorganism has been studied in less than 10 infections.
In addition, Quimox eye drops are used in the following cases:
- Treatment of corneal ulcers.
- Use before and after surgery to prevent infection.
Dosage
Adults and elderly (≥ 65 years)
Insert 1 drop into the affected eye 3 times/day for 7 days. The inflammation usually improves after 5 days, treatment should be continued for 2-3 more days. If the inflammation does not improve after 5 days of treatment, the diagnosis and/or treatment should be reconsidered.
Children
No dosage adjustment is required.
People with liver and kidney failure
No dosage adjustment is required.
Contact
